Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.36 |
| ▸ | MAPT | P10636 | 8/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.36 |
| ▸ | MEN1 | O00255 | 7/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25745858 | 0.80 | MAPT (0.39) | ALDH1A1MAPTKMT2AMEN1POLB | |
| SCHEMBL24007323 | 0.79 | KDM4E (0.42) | ALDH1A1MAPTKMT2AMEN1POLB | |
| SCHEMBL24007289 | 0.79 | POLB (0.36) | ALDH1A1MAPTKMT2AMEN1POLB | |
| SCHEMBL24007329 | 0.76 | HCRTR1 (0.38) | ALDH1A1POLBMDM2 | |
| SCHEMBL24816287 | 0.76 | POLB (0.35) | ALDH1A1MAPTKMT2AMEN1POLB | |
| SCHEMBL25746166 | 0.72 | KDM5B (0.34) | ALDH1A1MAPTKMT2APOLBKDM5B | |
| SCHEMBL24813442 | 0.72 | POLB (0.33) | ALDH1A1MAPTKMT2APOLBKDM5B | |
| SCHEMBL27853895 | 0.71 | MAPT (0.48) | ALDH1A1MAPTKMT2AMEN1LMNA | |
| SCHEMBL16150794 | 0.71 | ALDH1A1 (0.47) | ALDH1A1MAPTKMT2AMEN1POLB | |
| SCHEMBL25746099 | 0.70 | LMNA (0.40) | ALDH1A1MAPTKMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | ALDH1A1 3735/4885MAPT 4844/4885KMT2A 462/4885 |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | ALDH1A1 3735/4885MAPT 4844/4885KMT2A 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.